Clinical Trials Directory

Trials / Conditions / Metastatic Kidney Cancer

Metastatic Kidney Cancer

14 registered clinical trials studyying Metastatic Kidney Cancer — 3 currently recruiting.

StatusTrialSponsorPhase
WithdrawnA Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari
NCT04889495
Pfizer—
RecruitingCARE1 Pragmatic Clinical Trial
NCT06364631
Gustave Roussy, Cancer Campus, Grand ParisPhase 3
CompletedCALM: Managing Distress in Malignant Brain Cancer
NCT06180460
Virginia Commonwealth UniversityN/A
RecruitingMeasuring Oncological Value of Exercise and Statin
NCT05796973
Tampere University HospitalPhase 3
UnknownToripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Ca
NCT04385654
West China HospitalPhase 2
RecruitingAn Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Bi
NCT04623502
University of Texas Southwestern Medical CenterN/A
TerminatedImpact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Rena
NCT03846128
University Hospital, Rouen—
UnknownDenosumab and Pembrolizumab in Clear Cell Renal Carcinoma
NCT03280667
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupPhase 2
WithdrawnPhase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery o
NCT03189186
University of California, IrvinePhase 1
CompletedImmunotherapy Study for Metastatic Renal Cell Cancer
NCT02035358
NewLink Genetics CorporationPhase 1
WithdrawnTrial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
NCT01355562
Loma Linda UniversityPhase 2
TerminatedSerum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
NCT00942058
Centre Hospitalier Universitaire de Saint Etienne—
TerminatedImpact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kid
NCT01336231
Centre Francois Baclesse—
CompletedNatural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
NCT00328861
National Cancer Institute (NCI)Phase 2